Merck Price Negotiation Lawsuit May Face Same Obstacles as 340B Takings Claims
Past 340B litigation highlights that takings challenges to the Medicare price negotiation program face an uphill battle.
340B
-
Read more: Merck Price Negotiation Lawsuit May Face Same Obstacles as 340B Takings Claims -
Read more: Many Hospitals Receiving Discounted Drugs May Not Offer Patients Pharmaceutical Assistance Many Hospitals Receiving Discounted Drugs May Not Offer Patients Pharmaceutical Assistance
There are no measures built into the 340B program to assure that discounts are being used to support care for low-income populations.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from April 2022.
-
Read more: Federal Court Halts Implementation of 340B Dispute Resolution Rule Federal Court Halts Implementation of 340B Dispute Resolution Rule
A U.S. District Court recently halted the implementation of a dispute resolution rule for the 340B Drug Pricing Program.
-
Read more: Ensuring 340B Discounts Trickle Down to Low-Income Patients Ensuring 340B Discounts Trickle Down to Low-Income Patients
Congress must take action to ensure these discounts benefit low-income 340B eligible patients, as intended.
-
Read more: HHS’s 340B Advisory Opinion: Helpful or Harmful? HHS’s 340B Advisory Opinion: Helpful or Harmful?
A recent advisory opinion released by HHS left many 340B advocates hungry for answers and pharmaceutical manufacturers frustrated.
-
Read more: Cuts to 340B Drug Reimbursement May be Harmful During COVID-19 Cuts to 340B Drug Reimbursement May be Harmful During COVID-19
Slashing Medicare reimbursement for safety-net hospitals may have devastating effects on the individuals who rely on these hospitals.
-
Read more: Duplicate Discounts Threaten the 340B Program During COVID-19 Duplicate Discounts Threaten the 340B Program During COVID-19
The 340B program, which provides discount drugs to safety-net hospitals, faces an uncertain future due to increased demand spurred by the COVID-19 pandemic.
-
Read more: To Address COVID-19 Disparities, 340B Hospitals Need More Flexibility To Address COVID-19 Disparities, 340B Hospitals Need More Flexibility
Increased flexibility for 340B covered entities is necessary to address COVID-19 disparities faced by marginalized communities.
-
Read more: PhRMA Sues HHS (Again) For Trying To Expand 340B Discounts To Orphan Drugs PhRMA Sues HHS (Again) For Trying To Expand 340B Discounts To Orphan Drugs
By Rachel Sachs For all those who have been following the ongoing fight between pharmaceutical companies and HHS over the 340B Program’s coverage of orphan drugs (I know you’re out there), last week PhRMA filed a new complaint challenging HRSA’s interpretive rule on the subject under the APA. For all those who are not (but…